Roger E McLendon Selected Research

Protein-Tyrosine Kinases (Tyrosine Kinase)

4/2011	Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3.
10/2009	EGFRvIII-targeted vaccination therapy of malignant glioma.
11/2002	Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Roger E McLendon Research Topics

Disease

99	Neoplasms (Cancer) 04/2024 - 01/2002
59	Glioma (Gliomas) 09/2023 - 01/2002
52	Glioblastoma (Glioblastoma Multiforme) 09/2023 - 11/2002
27	Brain Neoplasms (Brain Tumor) 12/2018 - 01/2002
14	Medulloblastoma 11/2021 - 01/2002
8	Hypoxia (Hypoxemia) 01/2016 - 08/2006
6	Ependymoma 01/2019 - 01/2002
6	Astrocytoma (Pilocytic Astrocytoma) 01/2019 - 01/2002
5	Carcinogenesis 01/2023 - 09/2011
3	Hypersensitivity (Allergy) 09/2023 - 11/2010
3	Meningioma (Meningiomas) 10/2013 - 01/2012
3	Melanoma (Melanoma, Malignant) 04/2013 - 01/2002
3	Diarrhea 07/2012 - 01/2004
3	Lymphopenia (Lymphocytopenia) 01/2012 - 03/2011
2	Neuroblastoma 01/2021 - 09/2007
2	Poliomyelitis (Polio) 01/2021 - 12/2017
2	Pituitary Neoplasms (Pituitary Adenoma) 01/2020 - 02/2008
2	alpha-Thalassemia 01/2017 - 04/2013
2	Intellectual Disability (Idiocy) 01/2017 - 04/2013
2	Central Nervous System Neoplasms 12/2013 - 09/2012
2	Leukemia 11/2013 - 10/2012
2	Fatigue 07/2012 - 12/2010
2	Oligodendroglioma 12/2009 - 01/2006
2	Breast Neoplasms (Breast Cancer) 08/2009 - 11/2003
2	Infections 02/2009 - 02/2008
2	Turcot syndrome 08/2008 - 04/2006

Drug/Important Bio-Agent (IBA)

24	ErbB Receptors (EGF Receptor)IBA 01/2023 - 01/2002
19	Monoclonal AntibodiesIBA 02/2016 - 03/2002
17	Temozolomide (Temodar)FDA LinkGeneric 12/2021 - 02/2003
13	Proteins (Proteins, Gene)FDA Link 01/2023 - 10/2006
13	epidermal growth factor receptor VIIIIBA 01/2023 - 01/2002
10	Bevacizumab (Avastin)FDA Link 01/2014 - 08/2006
9	Irinotecan (Camptosar)FDA LinkGeneric 01/2014 - 01/2002
9	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2014 - 08/2006
8	O(6)-benzylguanineIBA 02/2012 - 05/2002
7	AntigensIBA 01/2018 - 01/2002
6	Telomerase (Telomerase Reverse Transcriptase)IBA 01/2023 - 04/2013
6	MethyltransferasesIBA 01/2019 - 10/2005
6	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2019 - 12/2009
6	Biomarkers (Surrogate Marker)IBA 12/2018 - 04/2013
6	Tyrosine Kinase InhibitorsIBA 07/2012 - 11/2002
5	EnzymesIBA 01/2023 - 02/2006
5	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 05/2005
5	VaccinesIBA 01/2018 - 09/2011
5	Peptides (Polypeptides)IBA 01/2013 - 01/2002
4	Immunotoxins (Immunotoxin)IBA 04/2016 - 01/2005
4	Small Interfering RNA (siRNA)IBA 08/2014 - 01/2008
4	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2014 - 11/2005
4	Phosphotransferases (Kinase)IBA 12/2006 - 01/2005
3	Glial Fibrillary Acidic ProteinIBA 01/2019 - 01/2002
3	RNA (Ribonucleic Acid)IBA 01/2017 - 12/2003
3	Carboplatin (JM8)FDA LinkGeneric 09/2016 - 12/2011
3	Neutralizing AntibodiesIBA 01/2013 - 08/2006
3	Erlotinib Hydrochloride (CP 358,774)FDA Link 07/2012 - 01/2010
3	Hydroxyurea (Hydrea)FDA LinkGeneric 01/2012 - 12/2005
3	Imatinib Mesylate (Gleevec)FDA Link 01/2012 - 12/2005
3	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 04/2011 - 11/2002
3	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2011 - 01/2005
3	TOR Serine-Threonine KinasesIBA 01/2010 - 01/2005
3	O(6)-Methylguanine-DNA MethyltransferaseIBA 12/2009 - 05/2002
3	Gefitinib (Iressa)FDA Link 02/2006 - 11/2002
2	Oxygen (Dioxygen)IBA 04/2024 - 10/2009
2	NucleotidesIBA 11/2021 - 01/2021
2	Immune Checkpoint InhibitorsIBA 01/2021 - 02/2016
2	VimentinIBA 01/2019 - 07/2009
2	Mucin-1 (CA 15-3 Antigen)IBA 01/2019 - 07/2009
2	poliovirus receptorIBA 12/2018 - 12/2017
2	Single-Chain AntibodiesIBA 01/2018 - 08/2010
2	Formaldehyde (Formol)FDA Link 12/2017 - 01/2016
2	ParaffinIBA 12/2017 - 01/2016
2	Histones (Histone)IBA 01/2017 - 10/2012
2	alpha-hydroxyglutarateIBA 01/2017 - 01/2013
2	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 01/2017 - 09/2014
2	Messenger RNA (mRNA)IBA 01/2017 - 02/2010
2	D2C7-(scdsFv)-PE38KDELIBA 04/2016 - 09/2013
2	AntibodiesIBA 02/2016 - 08/2010
2	MicroRNAs (MicroRNA)IBA 01/2016 - 10/2014
2	Membrane Proteins (Integral Membrane Proteins)IBA 09/2014 - 05/2010
2	Transcription Factors (Transcription Factor)IBA 08/2014 - 04/2011
2	Carbonic Anhydrase IXIBA 01/2014 - 01/2008
2	Lysine (L-Lysine)FDA Link 11/2013 - 10/2012
2	SteroidsIBA 10/2013 - 01/2005
2	Alkylating AgentsIBA 08/2013 - 04/2006
2	Angiogenesis InhibitorsIBA 02/2013 - 04/2011
2	Anticonvulsants (Antiepileptic Drugs)IBA 02/2013 - 02/2006
2	GangliosidesIBA 11/2010 - 01/2010
2	Sirolimus (Rapamycin)FDA Link 01/2010 - 02/2006
2	Immunoglobulin G (IgG)IBA 01/2010 - 06/2006
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2010 - 02/2006
2	Trastuzumab (Herceptin)FDA Link 08/2009 - 11/2003
2	Alkyl and Aryl TransferasesIBA 02/2009 - 10/2006
2	Adenosine Triphosphate (ATP)IBA 05/2007 - 12/2005

Therapy/Procedure

50	Therapeutics 01/2023 - 01/2002
18	Drug Therapy (Chemotherapy) 01/2021 - 01/2002
15	Radiotherapy 01/2019 - 01/2002
9	Immunotherapy 01/2021 - 10/2009
2	Catheters 12/2018 - 08/2009
2	Transplantation 01/2016 - 02/2012
2	Chemoradiotherapy 01/2016 - 01/2011
2	Craniotomy 08/2013 - 02/2008